| 拓扑替康联合大剂量化疗治疗复发、难治性非霍杰金淋巴瘤 |
| |
| 引用本文： | 陈林,娄世锋,陈姝,邓建川,罗云.拓扑替康联合大剂量化疗治疗复发、难治性非霍杰金淋巴瘤[J].中国新技术新产品精选,2003(10). |
| |
| 作者姓名： | 陈林 娄世锋 陈姝 邓建川 罗云 |
| |
| 作者单位： | 重庆医科大学附属第二医院血液科 400010
(陈林，娄世锋，陈姝，邓建川)，重庆医科大学附属第二医院血液科 400010(罗云) |
| |
| 摘 要： | 目的 观察拓扑替康 (topotecan)联合大剂量化疗治疗复发、难治性非霍杰金淋巴瘤 (NHL)的临床疗效、毒副作用、血浆LDH水平变化。方法 以拓扑替康联合大剂量Ara C、顺铂、地塞米松治疗复发、难治性NHL1 2例 ,其中复发 1 0例、难治 2例 ,治疗前后测定血浆LDH水平及常规血液、生化指标 ,评价临床疗效和毒副作用。结果 临床总有效率 6 7% ,其中CR4 2 % ,PR2 5 % ,骨髓抑制明显 ,治疗后血浆LDH水平明显下降。结论 拓扑替康联合大剂量化疗治疗复发、难治性NHL疗效较好 ,毒副作用尚可耐受 ,值得进一步研究
|
| 关 键 词： | 拓扑替康 非霍杰金淋巴瘤 大剂量化疗 |
High dose chemotherapy with topotecan :treatment for patients with relapsed or refractory non-Hodgkin's lymphoma |
| |
| CHEN Lin,LOU Shi feng,CHEN Shu,et al.High dose chemotherapy with topotecan :treatment for patients with relapsed or refractory non-Hodgkin's lymphoma[J].Chinese Selected New Technologies and Products,2003(10). |
| |
| Authors: | CHEN Lin LOU Shi feng CHEN Shu |
| |
| Abstract: | Objective To investigate the clinical curative effects of topotecan plus high dose chemotherapeutic drugs in treatment for patients with relapsed or refractory non Hodgkin's lymphoma (NHL). Methods Twelve patients including 10 with relapsed and 2 with refractory NHL were treated with combined chemotherapy containing topotecan, high dose Ara C, cisplatin, and dexamethasone. The plasma LDH level was determined, and hematologic routine examinations were done before and after treatment. The clinical curative effects and side effects were also evaluated. Results The total response rate was 67%, including CR42% and PR25%.The bone marrow suppression was evident, and the plasma LDH level markedly decreased after treatment. Conclusion Topotecan plus high dose chemotherapeutic drugs are effective in treatment for patients with relapsed or refractory non Hodgkin's lymphoma (NHL). |
| |
| Keywords: | topotecan non Hodgkin's lymphoma (NHL) high dose chemotherapy |
| 本文献已被 CNKI 等数据库收录！ |
|
